Antag疗法保证80万欧元,以便在临床试验中推进每周的肥胖症治疗。 Antag Therapeutics secures €80M to advance weekly obesity treatment in clinical trials.

一家生物制药公司 -- -- Antag Petrotics -- -- 已经获得8 000万欧元的资金,用于推进其肥胖症治疗,AT-7687,这是针对Glucose-Depended Insulinotropic Insulotropetide受体(GIPR)的每周注射。 Antag Therapeutics, a biopharmaceutical firm, has secured €80 million in funding to advance its obesity treatment AT-7687, a weekly injection that targets the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR). 该基金由Versant Ventures牵头,将支持临床试验,探讨AT-7687作为独立的治疗,并与GLP-1疗法相结合。 The financing, led by Versant Ventures, will support clinical trials exploring AT-7687 as both a standalone treatment and in combination with GLP-1 therapies. 该公司旨在改善肥胖症和新陈代谢健康结果。 The company aims to improve obesity and metabolic health outcomes.